Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued

Merck & Co., Inc.

2024-FY EPS reported $6.74 revenue$64,168,000,000

Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).
Q4 GAAP EPS $1.48; Non-GAAP EPS $1.72 (includes $0.23 charge for licensing).
KEYTRUDA full-year sales $29.5B (+18% YoY; +22% ex-FX).
WINREVAIR full-year sales $419M; GARDASIL declined 3% to $8.6B on lower China demand.
FY2025 guidance: sales $64.1-65.6B; Non-GAAP EPS $8.88-9.03 (incl. ~$0.09 LaNova charge).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.